Skip to main content

Table 5 Blood products and hemostatics according to patients in the state of moderate or severe shock

From: The trauma patient in hemorrhagic shock: how is the C-priority addressed between emergency and ICU admission?

  ER
BE -2 to -6 BE < -6
pRBC transfusion, n (%) 178/257 (69.3) 207/258 (80.2)
pRBC mass transfusion ≥10, n (%) 58/257 (22.6) 109/258 (42.2)
pRBC, median (IQR) 4.0 (0–8.0) 7.0 (2.0–16.5)
FFP transfusion, n (%) 145/257 (56.4) 176/271 (68.2)
FFP, median (IQR) 3.0 (0–7.11) 6.0 (0–14.3)
FFP:pRBC ratio 0.95 0.80
Platelet concentrates, n (%) 46/257 (17.9) 93/258 (36.0)
Platelet concentrates, median (IQR) 0 (0–0) 0 (0–1.8)
Platelet concentrates, mean (SD) 0.4 (1.2) 1.3 (3.9)
Fibrinogen, n (%) 40/171 (23.4) 62/176 (35.2)
PPSB, n (%) 30/171 (17.5) 42/176 (23.9)
Recombinant factor VIIa, n (%) 9/171 (5.3) 16/176 (9.1)
Antifibrinolytics, n (%) 13/171 (7.6) 21/176 (11.9)
Others, n (%) 21/171 (12.3) 32/176 (18.2)
  1. Transfused packed red blood cell concentrates (pRBCs), fresh frozen plasma (FFP) and hemostatics according to the subgroups of patients in the state of moderate (BE -2 to -6) and severe shock (BE < -6) upon ER admission.